The Pharmacy Times® Pharmacy Hospital Clinical Role section is a comprehensive resource for clinical news and expert insights on issues pertaining to hospital and health-system pharmacists.
November 13th 2024
RSV vaccination is approximately 77% to 81% effective against hospital and emergency department encounters among older adults.
New Legislation for Drug Shortages Praised by Health Care Groups
October 30th 2019Multiple health care organizations, including The American Hospital Association (AHA), the Institute for Safe Medication Practices (ISMP), and the American Society of Health-System Pharmacists (ASHP), have shown their full support for the MEDS Act.
Read More
Strategies for Operating a Long-Term-Care Pharmacy
October 27th 2019Attendees of a session on operating a long-term-care (LTC) pharmacy received tips on key metrics, technology advancements, and meeting customer needs, during the National Community Pharmacists Association (NCPA) 2019 Annual Convention.
Read More
New Treatment for CABP Receives FDA Approval
October 25th 2019Officials with the FDA have expanded the use of Melinta Therapeutics’ delafloxacin (Baxdela) to include treatment of adult patients with community-acquired bacterial pneumonia caused by designated susceptible bacteria, but the drug’s availability will be delayed for this new indication.
Read More
Bedtime Hypertension Treatment More Effective Than Morning Treatment
October 25th 2019Researchers have found that patients with high blood pressure (BP) who take all their antihypertensive medications at bedtime have better controlled blood pressure and a significantly lower risk of death or illness caused by heart or blood vessel problems, compared to patients who take their medications in the morning.1
Read More
Combination Therapy Shown to Increase Overall Survival and Progression-free Survival for HCC
October 24th 2019Genentech has announced the results of a Phase III study which showed that atezolizumab (Tecentriq) in combination with bevacizumab (Avastin) increased overall survival and progression-free survival in patients with unresectable hepatocellular carcinoma (HCC).
Read More
FDA Approves Therapy for Children with Lower Limb Spasticity
October 24th 2019Officials with the FDA have approved Allergan’s supplemental Biologics License Application (sBLA) for onabotulinumtoxinA (BOTOX®) to expand its indication to include treatment of pediatric patients, ages 2 to 17 years, with lower limb spasticity, excluding spasticity caused by cerebral palsy.
Read More
Studies Test Revefenacin Safety, Efficacy in Patients with COPD
October 23rd 2019Results from the safety and efficacy trial of revefenacin (REV) demonstrated that the drug had a safety profile similar to foremoterol (FOR). In addition, patients with COPD in the suboptimal peak inspiratory flow rate trial (sPIFR) showed lower weight, BMI, and lung function in comparison to patients with optimal peak inspiratory flow rate (oPIFR) in a second study.
Read More
Provider Collaboration Prevents Medication Errors in the Oncology Setting
October 22nd 2019At the ESMO Congress 2019, Sara Tolaney, MD, MPH, of Dana-Farber Cancer Institute, spoke about how a collaborative program between pharmacists and oncology providers at her institution helps prevent medication errors.
Read More
Opioid Litigation Settled for $260 Million in Lieu of Federal Trial
October 21st 2019Four pharmaceutical distributors have agreed to settle federal litigation related to the ongoing opioid epidemic for a collective $260 million, less than a day before a federal trial was set to begin in Ohio.
Read More
New Treatment Available for “Off” Episodes in Patients with Parkinson Disease
October 16th 2019Kyowa Kirin’s istradefylline (Nourianz) is now available in the United States as adjunctive treatment to levodopa/carbidopa in adult patients with Parkinson’s disease (PD) that are experiencing “off” episodes.
Read More
FDA Approves Rivaroxaban for Blood Clots in Acutely Ill Medical Patients
October 14th 2019To date, the FDA has granted rivaroxaban 8 indications, 6 of which are specifically for the treatment, prevention, and reduction in the risk of recurrence of venous thromboemolism across a wide range of patient populations.
Read More
Researcher Awarded $7.5 Million in Funding for COPD Research
October 13th 2019A researcher at the Washington University School of Medicine in St.Louis has received close to $7.5 million in total funding for research towards development of stem cell-based treatments for chronic pulmonary disease (COPD), asthma, and other disorders.
Read More